Dr. Hardy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
22 S. Greene Street
UMGCC; Room 9NE12
Baltimore, MD 21201Phone+1 410-328-1230Fax+1 410-328-1975- Is this information wrong?
Education & Training
- National Cancer InstituteFellowship, Stem Cell Transplantation and Immunotherapy, 2003 - 2006
- National Institutes of Health Clinical CenterFellowship, Infectious Disease, 1999 - 2003
- Duke University HospitalFellowship, Hematology and Medical Oncology, 1998 - 2001
- Duke University HospitalFellowship, Hematology and Medical Oncology, 1998 - 1999
- Duke University HospitalResidency, Internal Medicine, 1995 - 1998
- University of Washington School of MedicineClass of 1995
Certifications & Licensure
- WA State Medical License 2010 - 2024
- MD State Medical License 2004 - 2024
- NC State Medical License 1998 - 2022
- DC State Medical License 2013 - 2014
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells Start of enrollment: 2010 Dec 10
- Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation Start of enrollment: 2011 Mar 30
- MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC Start of enrollment: 2015 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells.Kline, K., Luetkens, T., Koka, R., Kallen, M., Chen, W., Ahmad, H., Omili, D., Iraguha, T., Gebru, E., Fan, X., Miller, A., Dishanthan, N., Baker, J., Dietze, K., Hank...> ;Cancer Immunology, Immunotherapy. 2024 Feb 13
- A novel multicolor fluorescent spot assay for the functional assessment of chimeric antigen receptor (CAR) T-cell products.Djordje Atanackovic, Thierry Iraguha, Destiny Omili, Stephanie V Avila, Xiaoxuan Fan, Mehmet Kocoglu, Etse Gebru, Jillian M Baker, Nishanthini Dishanthan, Kenneth A Di...> ;Cytotherapy. 2024 Apr 1
- 3 citationsImaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response byF-FDG PET/CT Imaging Following CAR-T Therapy.Lutfi, F., Goloubeva, O., Kowatli, A., Gryaznov, A., Kim, D., Dureja, R., Margiotta, P., Matsumoto, L., Bukhari, A., Ahmed, N., Mushtaq, M., Law, J., Lee, S., Kocoglu,...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Oct 1
- Join now to see all
Abstracts/Posters
- Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predicti...Nancy M. Hardy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain BarrierNancy M. Hardy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
- Hardy: HSCT for the Intensivist: Indications, Interventions, & ComplicationsJanuary 8th, 2017
Professional Memberships
- Member
- Fellow
- Member
- Member
- Society for the ImmunoTherapy of CancerMember
- American Society for Blood and Marrow TransplantationMember
Hospital Affiliations
- University of Maryland Medical CenterBaltimore, Maryland
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: